FDA "Has Harmed Public Health"

18 December 1997

Under David Kessler, the US Food and Drug Administration wielded itspower in making decisions that harmed rather than helped the public health, claims a study from the Institute for Policy Innovation.

For example, says the study, prescribing drugs for off-label uses is perfectly legal and widely accepted, yet the FDA banned companies from sharing the finding that aspirin can prevent heart attacks because it had not approved aspirin for this off-label use. "Never mind the fact that sound science" had made this discovery, it says, "the FDA wanted to be the decision maker, and made off-label uses more dangerous by squelching even information about safe dosage levels."

Citing other examples in the silicone breast implant and home HIV test area, study author Robert Goldberg concludes: "it would be a mistake to assume that it would be possible to reinvent the FDA by appointing a new commissioner. Kessler's use of power set a standard and transformed the way the FDA operates."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight